Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens | Zendy

David M. Livermore | Zendy; Shazad Mushtaq | Zendy; Marina Warner | Zendy; Simon Turner | Zendy; Neil Woodford | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens

Author(s) -

David M. Livermore,

Shazad Mushtaq,

Marina Warner,

Simon Turner,

Neil Woodford

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx360

Subject(s) - cefepime , tazobactam , cephalosporin , microbiology and biotechnology , acinetobacter , enterobacteriaceae , antibiotics , medicine , carbapenem , biology , imipenem , antibiotic resistance , escherichia coli , biochemistry , gene

Early β-lactamase inhibitors were combined with established penicillins, but different combinations may be more appropriate to counter current β-lactamase threats, with development facilitated by the US Generating Antibiotic Incentives Now (GAIN) Act. Cefepime/tazobactam is especially attractive, combining an AmpC-stable cephalosporin with a clinically established inhibitor, active against ESBLs and suitable for high-dose administration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research